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Abstract: Aspirin (ASA) hypersensitivity comprises types I to III
(Cox-1 mediated) and types IV and V (IgE antibody mediated).
Rapid, low-dose (81–325 mg/day) ASA desensitization regimens
are known to be useful in establishing ASA tolerance in patients
with coronary artery disease and coexisting ASA/nonsteroidal
anti-inﬂammatory drug hypersensitivity. We document 3 cases in
Vietnam of desensitization to ASA in patients with coronary
artery disease and coexisting ASA hypersensitivity. One of these
3 patients had probable immune-mediated hypersensitivity,
whereas the remaining 2 had probable Cox-1–mediated reactions.
The regimen of desensitization we employed for each patient was
designed to account for the probable mechanism of hypersensitiv-
ity in the individual and further modiﬁed according to the degree
of tolerance observed, with all 3 patients eventually achieving
a daily cardioprotective dosage of ASA.
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In 1971, British pharmacologist John Vane demonstrated thataspirin [acetylsalicylic acid (ASA)], an inhibitor of platelet
activation and aggregation, irreversibly inhibits the platelet-
dependent enzyme cyclooxygenase (COX), thereby preventing
the synthesis of prostaglandins. Subsequent researchers identi-
ﬁed 2 COX isoenzymes: COX-1 and COX-2.1,2 In platelets,
the COX-1 enzyme produces thromboxane A2, a powerful
promoter of platelet aggregation. Thus, aspirin, by irreversibly
inactivating COX-1, blocks the generation of thromboxane
A2, thereby exerting its antiplatelet effect. The role of ASA
in the primary and secondary prevention of cardiovascular
events has been established recently and treatment with anti-
platelet agents including ASA can lead to a 31% event
reduction rate.3 However, some patients are unable to tolerate
acetylsalicylic acid (aspirin) due to hypersensitivity.
ASA hypersensitivity comprises 5 distinct types, types I
to III (Cox-1 mediated) and types IV and V type (IgE antibody
mediated), with the classiﬁcation based on the mechanism of
hypersensitivity, risk factors, and cross sensitivity to non-
steroidal anti-inﬂammatory drugs (NSAIDs). Type I hyper-
sensitivity manifests as respiratory symptoms such as rhinitis
and asthma. Type II is observed in patients with chronic
idiopathic urticaria and manifests as angioedema and an
exacerbation of the urticaria. Urticaria and angioedema occurs
in type III hypersensitivity without chronic idiopathic urticaria,
with these symptoms occurring after the ﬁrst dose of aspirin or
NSAID. Types IV and V hypersensitivities, on the other hand,
are mediated by aspirin-directed immunoglobulin E antibodies
that rarely cross-react with other NSAIDs. Patients with type
IV reactions present with angioedema and urticaria, whereas
type V reactions are typical of anaphylaxis.4
The incidence of ASA hypersensitivity ranges in the
general population from 0.6% to 2.5%, and in adults with
asthma, it ranges from 4.3% to 11%5,6; however, the preva-
lence of ASA hypersensitivity among individuals with coro-
nary artery disease (CAD) in the Asia-Paciﬁc region is not
known precisely.7 Notwithstanding, low-dose (81–325 mg/d),
rapid ASA desensitization regimens appear to be useful in
patients from countries other than Vietnam in the Asia-Paciﬁc
region, who have CAD and coexisting ASA/NSAID hyper-
sensitivity, including those who have undergone percutane-
ous coronary intervention.7
Our report documents 3 cases in Vietnam of desensi-
tization to ASA in patients with CAD and coexisting aspirin
hypersensitivity. One of these 3 patients had probable
immune-mediated hypersensitivity, whereas the remaining
2 had probable COX-1–mediated reactions. Several protocols
for ASA desensitization have been published, and the proto-
cols have been summarized.4,8
In our series, we chose to employ a regimen of
desensitization for each patient that was designed or selected
by us to account for both the probable mechanism of
hypersensitivity operative in the individual and their clinical
state. These slower protocols were then further modiﬁed
according to the degree of tolerance observed. All 3 patients
eventually achieved a cardioprotective dosage of aspirin
delivered in a single daily dose.
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A 43-year-old Vietnamese man, referred to the Center of
Allergology and Clinical Immunology, Bach Mai Hospital,
Hanoi, Vietnam, had had asthma since childhood and had
previously experienced episodes of angioedema after the
ingestion of minor, nonprescription analgesics (precise constit-
uents unknown). He had been given 75 mg of clopidogrel and
300 mg of ASA before the planned insertion of percutaneous
cardiac stents. Within 30 minutes thereafter, he had developed
sneezing, periobital angioedema, and pharyngeal discomfort,
which settled after antihistamine was administered.
Investigations
His spirometry was normal. Skin prick testing with
ASA 1 mg/mL was positive. Total serum IgE was 106 U/L
(normal range , 100 U/L). Ear, nose, and throat examination
and nasal/sinus computed tomography scans were normal.
Results
In view of the likely immune-mediated mechanism
operative in this patient and his compromised cardiac status,
ASA desensitization began with 0.0001 mg of ASA. Initially,
doses were doubled each 30 minutes, provided the peak
expiratory ﬂow was not reduced. Breakthrough symptoms,
which settled with 180 mg of fexofenadine, occurred
10 minutes after a single dose of 50 mg and the protocol
was further modiﬁed, by returning to lower doses which had
been tolerated and decreasing the rate of dosage increase
thereafter (see Table 1). By day 10, the patient tolerated
100 mg daily in a single dose, and he continues to do so.
Case 2
History
A 76-year-old Vietnamese man, with CAD requiring
urgent stenting, presented to the Center of Allergology and
Clinical Immunology, Bach Mai Hospital, Hanoi, Vietnam,
with urticaria, which occurred only after aspirin ingestion.
The onset of abdominal pain, nausea, and vomiting was noted
to have occurred coincidentally with the suspected aspirin
hypersensitivity.
Investigations
Spirometry and otolaryngological examination were
normal. Total serum IgE was 1337 U/L (normal range ,
100 U/L). Ascaris lumbricoides ova and parasites were iden-
tiﬁed in feces. Enzyme-linked immunosorbent assay for Tox-
ocara and liver ﬂuke was positive (1:3200 dilution).
Results
ASA desensitization was ceased after breakthrough
symptoms at 100 mg; 400 mg of albendazole per day was
given for 3 days. The protocol was then modiﬁed by starting
at a lower dose and slowing the tempo of the dosage increases
over a 6-day period. This patient now tolerates a daily dose of
100 mg of ASA (see Table 1).
Case 3
History
Three years before his referral to the Center of
Allergology and Clinical Immunology, Bach Mai Hospital,
Hanoi, Vietnam, a 66-year-old Vietnamese man had been
prescribed ASA for stable angina. However, ASA had been
ceased 1 year before the presentation due to supervening ASA
hypersensitivity manifest as urticaria. In addition, he had a
history of a transient ischemic attack 2 years ago and
childhood asthma. On this occasion, he had been admitted
with a myocardial infarct, prompting consideration of ASA
desensitization.
Investigations
Total serum IgE was 570 U/L (normal range , 100 U/
L). Ascaris lumbricoides ova and parasites were negative in
feces, and enzyme-linked immunosorbent assay for Toxocara
and liver ﬂuke was negative. There was no abnormality on
ear, nose, and throat examination or thoracic examination.
Results
Initial desensitization with ASA was complicated by
urticaria occurring 2 hours after the last dose of 100 mg. The
protocol was then modiﬁed by starting at a lower dose and
slowing the tempo of the dosage increases over a 6-day
period. This patient now tolerates a daily dose of 100 mg of
ASA (see Table 1).




























1 Angioedema/urticaria Fexofenadine 0.0001 100 30 10 No 8
2 Urticaria Fexofenadine 10 100 90 6 No 6
3 Urticaria Fexofenadine 10 100 90 6 No 3
*Initial dose of ﬁnal protocol (milligram).
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DISCUSSION
In this report, we have documented 3 cases in Vietnam
of desensitization to ASA in patients with CAD and
coexisting aspirin hypersensitivity. Although the precise
prevalence of ASA hypersensitivity remains to be determined
in Vietnam, our report indicates that the condition exists in
the Vietnamese population in both immune-mediated types
and the COX-1–mediated types of reactivity. The patient
described in case 1, with a skin test positive at 1 mg/mL of
ASA and angioedema and urticaria after ASA, appears most
likely to have type IV hypersensitivity. On the other hand, the
patients described in cases 2 and 3, with urticaria occurring
only after ASA ingestion, have a type III, COX-1–mediated
reaction pattern. We are unable to comment upon whether the
full range of hypersensitivity types occur in the Vietnamese
due to the small numbers in this initial series; however, clin-
ical experience with patients other than those described here
indicates that types I, II, and V ASA hypersensitivity do occur
in the Vietnamese.
Several protocols for ASA desensitization, identiﬁed by
MEDLINE search, have been published between 1996 and
2006, and these were reviewed by Page and Schroeder in
2007.8 Rapid, low-dose (81–325 mg/d) ASA desensitization
regimens are known to be useful in establishing ASA toler-
ance in patients with CAD and coexisting ASA/NSAID hyper-
sensitivity. These protocols are invariably useful as a starting
point for ASA desensitization; however, in our experience, to
achieve desensitization in an individual patient, modiﬁcation
may be necessary, and ab initio consideration of both the
probable mechanism of hypersensitivity operative in the indi-
vidual and their clinical state is helpful in designing or select-
ing a regimen of desensitization for each patient. Thus, in view
of the likely immune-mediated mechanism operative in the
patient described as case 1 and his compromised cardiac sta-
tus, ASA desensitization began with 0.0001 mg of ASA and
doses were doubled each 30 minutes. However, in the patients
described in cases 2 and 3, with probable COX-1–mediated
hypersensitivity, initial doses of 10 mg were used. Arguably,
the need for modiﬁcation may have been due to our reliance
upon fexofenadine alone as pretreatment in our patients, as
some other investigators, Wong et al9 and Silberman et al,10
have employed montelukast and/or oral corticosteroids as pre-
treatment medications in their desensitization regimens.
Rossini et al,11 Hobbs and Lyle12 and Dalmau et al,13 how-
ever, used no pretreatment medications and achieved similar
success to Wong et al9 and Silberman et al10 [pooled success
rate for protocols utilizing pretreatment regimens 87.5% (21 of
24 subjects) and pooled success rate for protocols not using
pretreatment regimens 89.4% (42 of 47 subjects)].
Although all 3 patients achieved a daily cardioprotec-
tive dosage of aspirin, breakthrough symptoms, which settled
after the administration of antihistamine (additional 180 mg
of fexofenadine), necessitated modiﬁcation of the regimen in
all 3 cases. In case 1, urticaria occurred 10 minutes after
a single dose of 50 mg. Thereafter, the protocol was modiﬁed,
by returning to lower doses that had been tolerated and
decreasing the rate of dosage increase thereafter, with a daily
dose of 100 mg in a single dose achieved by day 10 and
a combined daily dose of at least 100 mg being achieved from
day 2. Intervals between doses of 30 minutes were thought
appropriate for this patient, given the immediate reaction he
demonstrated. In cases 2 and 3, breakthrough symptoms of
urticaria occurred 2 to 3 hours after the ﬁrst dose of 100 mg
given during the desensitization. Modiﬁcation of the regimen,
returning to lower doses which had been tolerated, increasing
the interval between doses (to 1.5 hours), and decreasing the
rate of dosage increase thereafter over a 6-day regimen, was
successful, with a daily dose of 100 mg in a single dose
achieved by day 6, with a daily dose of 100 mg achieved from
day 2 onward, in both cases. In case 2, ASA desensitization
had been ceased when breakthrough symptoms occurred, and
albendazole was administered for parasitism before the ASA
desensitization was resumed, in case helminthic infestation
was present, and it was promoting the occurrence of the
urticaria. It is interesting to speculate that the difﬁculty in
achieving tolerance to a single daily dose of 100 mg in the
patients described as cases 2 and 3 may relate to their
underlying parasitism, which may have aggravated their
tendency to produce urticarial lesions.14
CONCLUSIONS
We conclude that both immune-mediated and COX-
1–mediated ASA hypersensitivity occur in Vietnamese
patients and that desensitization with ASA is successful in
these individuals, albeit with appropriate modiﬁcation of the
ASA desensitization protocols both ab initio, according to
the probable mechanism of hypersensitivity operative and
the clinical state of the patient, and during desensitization,
according to the clinical progress of the patient.
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